NUS NU SKIN ENTERPRISES, INC.
Wholesale-Drugs, Proprietaries & Druggists' Sundries · NYSE · SEC CIK 1021561 · Fiscal year ends 12/31
Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters
Growth
TTM revenue YoY-15.3%
TTM net income YoY-313.7%
TTM EPS YoY-321.9%
Revenue 3-yr CAGR-12.9%
Net income 3-yr CAGR—
Margins
Gross margin67.8%
Operating margin-2.0%
Net margin-17.7%
FCF margin-2.0%
EBITDA margin1.8%
Returns
ROE-34.8%
ROA-18.6%
ROIC (approx.)-3.1%
Asset turnover1.05x
Leverage & solvency
Liabilities / assets49.7%
Debt / equity0.37x
Current ratio2.04x
Interest coverage-1.79x
Cash quality & payout
Operating cash flow / net income-0.06x
Accruals ratio-19.9%
Payout ratio—
Capex / revenue3.1%
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | 2026Q32026-09-30 | 2026Q22026-06-30 | 2026Q12026-03-31 | 2025Q4*2025-12-31 | 2025Q32025-09-30 | 2025Q22025-06-30 | 2025Q12025-03-31 | 2024Q4*2024-12-31 |
|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||
| Revenue | $311.01M | $320.11M | $320.61M | $370.32M | $364.21M | $386.14M | $364.49M | $445.55M |
| Cost of revenue | $108.84M | $101.79M | $106.14M | $108.34M | $107.49M | $120.41M | $117.53M | $166.41M |
| Gross profit | $202.17M | $218.32M | $214.46M | $261.98M | $256.72M | $265.73M | $246.96M | $279.15M |
| SG&A expense | $93.87M | $90.85M | $98.54M | $107.39M | $104.82M | $106.72M | $113.20M | $120.93M |
| Operating income | $5.09M | -$59.32M | $4.03M | $23.24M | $21.64M | $30.78M | -$9.90M | -$53.08M |
| Interest expense | $3.50M | $3.32M | $4.25M | $3.99M | $4.14M | $2.53M | $3.28M | $5.86M |
| Pretax income | $1.89M | -$63.17M | $2.60M | $18.19M | $15.99M | $27.41M | $134.60M | -$57.80M |
| Income tax | $2.63M | $186.62M | $763,000 | $3.70M | -$1.08M | $6.29M | $27.09M | -$21.70M |
| Net income | -$742,000 | -$249.80M | $1.84M | $14.49M | $17.08M | $21.12M | $107.52M | -$36.10M |
| EBITDA | $17.62M | -$46.66M | $16.37M | $36.16M | $33.73M | $43.83M | $4.30M | -$36.63M |
| EPS (basic) | -0.02 | -5.14 | 0.04 | — | 0.35 | 0.43 | 2.16 | — |
| EPS (diluted) | -0.02 | -5.14 | 0.04 | — | 0.34 | 0.43 | 2.14 | — |
| Weighted avg. shares (diluted) | 48.68M | 48.60M | 49.42M | — | 50.31M | 49.50M | 50.33M | — |
| Balance sheet | ||||||||
| Cash & equivalents | $164.90M | $189.64M | $198.65M | $238.63M | $251.79M | $264.16M | $203.77M | $186.88M |
| Short-term investments | $1.74M | $1.74M | $1.75M | $1.21M | $1.21M | $1.21M | $9.78M | $11.11M |
| Receivables | $51.41M | $48.90M | $45.01M | $39.54M | $48.89M | $59.70M | $56.58M | $50.78M |
| Inventory | $191.66M | $191.50M | $178.60M | $178.64M | $178.53M | $180.38M | $188.78M | $190.24M |
| Current assets | $479.42M | $508.15M | $522.89M | $547.70M | $548.14M | $571.55M | $524.86M | $538.60M |
| PP&E, net | $382.94M | $379.55M | $381.61M | $377.17M | $375.28M | $374.21M | $380.07M | $379.60M |
| Goodwill | $4.75M | $4.75M | $83.62M | $83.62M | $83.62M | $83.62M | $83.62M | $83.62M |
| Intangibles | $36.38M | $37.88M | $39.29M | $42.61M | $44.20M | $45.94M | $47.55M | $74.28M |
| Total assets | $1.09B | $1.12B | $1.38B | $1.41B | $1.42B | $1.44B | $1.39B | $1.47B |
| Current liabilities | $235.19M | $256.35M | $257.00M | $263.73M | $254.44M | $283.91M | $260.30M | $296.61M |
| Short-term debt | $20.00M | $20.00M | $20.00M | $20.00M | $20.00M | $35.00M | $20.00M | $30.00M |
| Long-term debt | $183.73M | $193.66M | $203.59M | $204.19M | $209.04M | $213.90M | $218.76M | $363.61M |
| Total debt | $203.73M | $213.66M | $223.59M | $224.19M | $229.04M | $248.90M | $238.76M | $393.61M |
| Total liabilities | $540.60M | $578.79M | $582.71M | $600.07M | $624.61M | $655.94M | $637.44M | $817.46M |
| Shareholders' equity | $547.48M | $542.74M | $794.09M | $805.24M | $799.79M | $787.75M | $753.97M | $651.46M |
| Net debt | $38.83M | $24.02M | $24.94M | -$14.44M | -$22.74M | -$15.26M | $34.99M | $206.73M |
| Cash flow statement | ||||||||
| Operating cash flow | -$8.12M | $10.62M | -$3.92M | $16.62M | $27.48M | $35.80M | $389,000 | $25.79M |
| Capital expenditure | $11.35M | $5.64M | $13.71M | $10.76M | $9.91M | $18,000 | $13.58M | $12.58M |
| Free cash flow | -$19.47M | $4.99M | -$17.63M | $5.86M | $17.57M | $35.78M | -$13.20M | $13.20M |
| Investing cash flow | -$5.15M | -$5.64M | -$14.29M | -$9.76M | -$9.91M | $8.79M | $181.54M | -$13.62M |
| Financing cash flow | -$13.47M | -$13.38M | -$20.40M | -$18.50M | -$26.88M | $9.27M | -$166.29M | -$43.63M |
| Depreciation & amortization | $12.54M | $12.66M | $12.34M | $12.91M | $12.09M | $13.05M | $14.21M | $16.45M |
| Stock-based compensation | $2.71M | $1.12M | $3.69M | $3.16M | $5.82M | $5.82M | $5.20M | $3.44M |
| Dividends paid | $2.93M | $2.91M | $2.87M | $2.91M | $2.96M | $2.96M | $3.00M | $2.98M |
| Share buybacks | $0 | $0 | $5.01M | $10.02M | $5.01M | $0 | $5.01M | $0 |
Free plan shows the latest 8 periods; Pro shows all 71 🔒
· Most companies do not report Q4 separately: Q4 = full year − first three quarters (marked *). EPS and share counts cannot be subtracted, so Q4 EPS is often blank; cash flow statements are year-to-date in quarterly reports, so single quarters are mostly derived.
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-21 06:27.